Cannabis for Palliative Care in Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age25+
SponsorUniversity of Colorado, Boulder
About this trial
Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) versus placebo on measures of sleep, pain, mood, subjective and objective cognitive functioning, and quality of life within 185 cancer patients.
Eligibility criteria
Qualifiers
Able to provide informed consent
Aged ≥25 years at Visit 1 (Baseline)
Have a diagnosis of any solid tumor type and is currently undergoing or has undergone either curative or palliative treatment in the past 18 months
Currently experiencing symptoms of sleep problems, pain, and/or mood disturbance (i.e., depression, anxiety)
Disqualifiers
Report of illegal drug use (e.g., cocaine, methamphetamine) in the past 90 days
Current use of anti-epileptic medications (e.g., clobazam, sodium valproate, lamotrigine)
Current use of medications known to have major interactions with Epidiolex (e.g., buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, teriflunomide)
Current use of anti-psychotic medications
Trial design
Treatments tested in this trial
- fsCBD Cannabidiol
- Placebo
- bsCBD Cannabidiol
Treatment groups
185 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov